Two rejections and a hostile review, then approval. Plus $8B for radiopharma
The obesity race got its answer this week. Plus Merck's RSV expansion and a China JV.
A surprise yes after a brutal review. Plus the AZ BMS merger is dead and Novo dips again.
An 11 drug CNS company is born, and analysts doubt the $400B mega merger.
The FT reports merger talks. Plus Novo's heart drug fails and Capricor bombs its adcomm.
It cut a drug that worked to chase the obesity prize. Plus BMS's Alzheimer's data slips.
Section 232 hits today. The exemptions decide everything. Plus earnings come in strong.
Altimmune's drug cut drinking in a trial. And the big tariffs land tomorrow.
Doubts land days before the adcomm. Plus GSK's $2.5B restructuring and tariffs Friday.
Argenx bought Forte for vitiligo and celiac. Meanwhile Sanofi's $1.4B bet fell apart.
Lilly's triple hormone drug delivered again. Plus tariffs hit Friday and Otsuka landed an ADHD approval.
Its first lung cancer drug, weeks after closing. Plus a transatlantic breast cancer split.
Indian pharma stocks fell hard. Plus pharma lobbies to soften the China restrictions.
The obesity giants are in federal court now. Plus Novartis opens earnings with 3% growth.
No one deals like Lilly. Plus the readouts that define the week ahead.
Novartis got full approval, Vera's in, Vertex is next. Plus a soft start to earnings season.
Merck cracked the first oral PCSK9. And we map how the China fight actually ends.
An unprecedented tau drop, a missed endpoint, an 8% slide. Plus Celcuity's first approval.
Its biggest China upfront yet, right before Friday. Plus injectable Leqembi gets cleared.
Operation TrialBlazer is the carrot. Friday's deadline is the stick. Both aimed at the same problem.
Wainua flunked Phase 3. Meanwhile the China deadline hits Friday and the deals keep landing.
Eight days to the July 17 deadline and the deals keep coming. Plus Krazati stumbles and GSK walks.
The fourth ten billion dollar deal of 2026. Plus Vera beat Vertex to market this week.
An 82% response rate in first line. Plus we got the Ipsen numbers wrong and are fixing it.
Divarasib beat approved therapy in Phase 3. Novartis grabbed another ADC platform.
